Redeye returns with an update following AlzeCure's Q1 2025 earnings release, which aligned with our expectations. AlzeCure has delivered several noteworthy news this year, especially regarding the EIC grant. The market has received this well, with the share price more than doubling year-to-date (albeit from low levels). We maintain our estimates but adjust for FX fluctuations in our model, resulting in an updated valuation.
LÄS MER
